Veterinary diagnostics CAG recurring revenue growth measures growth in recurring companion-animal diagnostic revenue under the issuer's reported or organic methodology.
IDEXX reported 11.0% CAG Diagnostics recurring revenue growth in the second quarter of 2026 and 10.3% organic growth after excluding currency effects.
Organic growth narrows the operating comparison
Reported growth can include foreign-exchange and acquisition effects. Organic growth is intended to isolate the operating change under IDEXX's own definition.
The measure should remain issuer-specific rather than being treated as a standardized industry growth rate.
Growth reflects both volume and price
IDEXX attributed the increase primarily to higher VetLab consumables and reference laboratory volumes, plus higher realized prices.
Pair the metric with VetLab consumables revenue and reference laboratory revenue to see where the recurring growth is coming from.
Primary source: IDEXX Q2 2026 Form 10-Q.
Part of the Veterinary Diagnostics Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- IDXXOpen operating-model research →10 of 10 reviewed concepts in Veterinary Diagnostics EconomicsRecurring diagnostic revenue engine4 of 4 bridge concepts supportedContinue through this bridge:CAG Recurring RevenueReference Laboratory RevenueVetLab Consumables Revenue
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare recurring diagnostics growth
Compare reported and organic recurring diagnostic growth while keeping currency, acquisitions, volume, and realized price separate.
Explore more topics in the Financial Research Encyclopedia.